Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management

Briefs: Alembic Pharmaceuticals and Tyche Industries

Alembic receives EIR from USFDA for facility at Panelav

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)

NATCO Pharma updates on acquisition of Adcock Ingram

FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

iPHEX 2025: Piyush Goyal calls for deeper global collaborations to strengthen healthcare systems worldwide

Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive

AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes

Fortis takes over 200-bed Greater Noida hospital on long term lease

Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran

Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives